Trilaciclib hydrochloride (G-1T28; Cosela), the hydrochloride salt of Trilaciclib, is a short-acting CDK4/6 inhibitor with anticancer activity.

Trilaciclib (G-1T28; G1T28; Cosela) is a novel, first-in-class and short-acting CDK4/6 inhibitor approved in 2021 by FDA as a medication to reduce the frequency of chemotherapy-induced bone marrow suppression.

CDK9-PROTAC (PROTAC CDK9 Degrader-1) is a novel, potent and selective CDK9 (Cyclin-dependent kinase 9) degrader.

Zotiraciclib diHCl (formerly TG02, SB1317) is an orally bioavailable, brain penetrant and multi-kinase (CDK/JAK2/FLT3) inhibitor for the treatment of cancer (e.g. anaplastic astrocytoma and GBM, as well as DIPG, a rare pediatric cance).

Flavopiridol (also known as Alvocidib, NSC 649890 HCl; HMR1275; L868275; HMR 1274; NSC649890), a broad spectrum and ATP-competitive inhibitor of CDKs with potential antineoplastic activity.

ON123300 is a novel, low molecular weight and potent multikinase inhibitor identified through a series of screens that supported further analyses for brain tumor chemotherapy.

K03861 (K0 3861; AUZ-454; K-03861; AUZ 454), an aminopyrimidine-phenyl urea analog, is novel and potent type II cyclin-dependent kinase-CDK2 inhibitor with potential anticancer activity.

Palbociclib (formerly PD-0332991; PD0332991; Pfizer trade name Ibrance) is a highly selective, orally bioavailable pyridopyrimidine-based CDK4/6 inhibitor that has been approved for cancer treatment.

Ebvaciclib (PF-06873600; PF06873600) is a novel, potent, selective and orally bioavailable pan-inhibitor of cyclin-dependent kinase (CDK) with potential antitumor activity.